Seminars in Immunology最新文献_第4页

Uncovered role of Th9 and IL-9 in rheumatoid arthritis: Current status and future directions Th9和IL-9在类风湿关节炎中的作用：现状和未来方向

IF 7.4 2区医学

Seminars in Immunology Pub Date : 2025-09-01 Epub Date: 2025-07-21 DOI: 10.1016/j.smim.2025.101979

Jiajie Tu , Weile Chen , Zimeng Xue , Lai-Shan Tam , Wei Wei

{"title":"Uncovered role of Th9 and IL-9 in rheumatoid arthritis: Current status and future directions","authors":"Jiajie Tu , Weile Chen , Zimeng Xue , Lai-Shan Tam , Wei Wei","doi":"10.1016/j.smim.2025.101979","DOIUrl":"10.1016/j.smim.2025.101979","url":null,"abstract":"<div><div>Early studies on T helper (Th) 9 cells and their specific cytokine IL-9 mainly focused on the field of allergic diseases. In addition to pathological studies, IL-9 can also affect the normal development and various functions of T cells and B cells. In recent years, a series of studies have found that IL-9 may play a pathogenic role in a range of autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and multiple sclerosis (MS). Specifically, Th9 cells and IL-9 show abnormally high expression in peripheral blood, synovial fluid, and synovial tissue of patients with RA. Based on this, therapeutic strategies targeting IL-9, such as monoclonal antibodies, have become potential treatments for RA. However, research on Th9 and IL-9 in RA has only been conducted for less than two decades, and many issues are worth further exploration. This article reviews the molecular mechanisms underlying the pathogenic effects of Th9 and IL-9 in RA, summarizes the potential reasons for inducing abnormally high expression of Th9 and IL-9 in RA, and discusses future research directions. The existing evidence shows that Th9-derived IL-9 is a potential biomarker or therapeutic target in RA. We hope that this current review can play a bridging role and provide new ideas for the study of Th9 and IL-9 in RA.</div></div>","PeriodicalId":49546,"journal":{"name":"Seminars in Immunology","volume":"79 ","pages":"Article 101979"},"PeriodicalIF":7.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144672082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Discovery and characterization of vertebrate sialoglycan-binding proteins 脊椎动物唾液聚糖结合蛋白的发现与表征

IF 7.4 2区医学

Seminars in Immunology Pub Date : 2025-09-01 Epub Date: 2025-07-18 DOI: 10.1016/j.smim.2025.101978

Liran Adler , Sharon Yehuda , Ajit Varki , Vered Padler-Karavani

{"title":"Discovery and characterization of vertebrate sialoglycan-binding proteins","authors":"Liran Adler , Sharon Yehuda , Ajit Varki , Vered Padler-Karavani","doi":"10.1016/j.smim.2025.101978","DOIUrl":"10.1016/j.smim.2025.101978","url":null,"abstract":"<div><div>All known life forms feature a dense ensemble of cell surface and extracellular glycans. In vertebrates this includes a high density of sialic acids (Sias), a family of acidic sugars typically capping glycans of cell surface or secreted glycoproteins and glycolipids. Since Sia was found to be the receptor for the influenza virus, many other pathogens have since been shown to recognize specific host sialoglycans as targets for their hemagglutinins, adhesins and toxins, often with remarkable specificity and high affinity/avidity. Other pathogens have evolved diverse mechanisms to evade host immunity by ‘molecular mimicry’ of host sialoglycans. Sialic acids also act as “biological masks”, preventing access to underlying structures. Until the late 1970s, it was assumed that endogenous sialoglycan-binding proteins (SGBPs) did not exist in vertebrates. Several such vSGBPs have since been discovered, characterized by distinct sialoglycan specificities but generally low affinity. Markedly different rates of evolution and “Red Queen” effects likely explain this striking difference from the high specificity and affinity/avidity of numerous microbial SGBPs (mSGBPs). Nevertheless, these vSGBPs play important roles in normal development, physiology and disease conditions, with implications for human evolution. This review describes the discovery and characterization of vSGBPs. Most are previously known proteins, and their sialoglycan recognition had been discovered serendipitously. Thus, we may be seeing the ‘tip of an iceberg’ with many more such proteins to be discovered. We also emphasize recent studies showing that SGBP properties are markedly affected by competing endogenous Sialomes, such that in vitro studies may need to be re-visited, under conditions present in vivo.</div></div>","PeriodicalId":49546,"journal":{"name":"Seminars in Immunology","volume":"79 ","pages":"Article 101978"},"PeriodicalIF":7.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144654212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A framework for the rational design of oncolytic viruses: A holistic perspective considering the tumour microenvironment 溶瘤病毒合理设计的框架：考虑肿瘤微环境的整体视角

IF 7.4 2区医学

Seminars in Immunology Pub Date : 2025-09-01 Epub Date: 2025-06-25 DOI: 10.1016/j.smim.2025.101977

Dylan Thomas , Priya Bharadwa , Timothy Lee , Carolina S. Ilkow

{"title":"A framework for the rational design of oncolytic viruses: A holistic perspective considering the tumour microenvironment","authors":"Dylan Thomas , Priya Bharadwa , Timothy Lee , Carolina S. Ilkow","doi":"10.1016/j.smim.2025.101977","DOIUrl":"10.1016/j.smim.2025.101977","url":null,"abstract":"<div><div>Oncolytic viruses have played a pioneering role in establishing immunotherapies as the next generation of anti-cancer medicines. Recent works have highlighted the impact the tumour microenvironment has on the efficacy of immunotherapies like oncolytic viruses, as well as the ability of oncolytic viruses to modulate and reconfigure this microenvironment. Within this review, we examine the vast and increasing evidence highlighting the pivotal role of tumour microenvironment in dictating oncolytic virotherapy efficacy, while also discussing potential avenues for the future development of oncolytic viruses. Following introductions to commonly used oncolytic viruses and components of the tumour microenvironment, we highlight recent research investigating their reciprocal relationships. Finally, innovations in 3D modelling to reconstitute the tumour microenvironment <em>ex vivo</em> are discussed, followed by examination of successful case studies in which tumour microenvironment dynamics have informed the rational design of successful and tailored oncolytic viruses. Through this, we provide evidence that substantial tumour heterogeneity amongst patients and tumour types significantly impedes effective oncolytic virotherapy, thus we suggest that consideration of each unique tumour microenvironment’s dynamics is critical for the design of functional and efficacious oncolytic virotherapy – both as a monotherapy or in combination with other cancer therapies.</div></div>","PeriodicalId":49546,"journal":{"name":"Seminars in Immunology","volume":"79 ","pages":"Article 101977"},"PeriodicalIF":7.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144470624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Autoimmune diabetes and targets for immunomodulation 自身免疫性糖尿病和免疫调节靶点

IF 7.8 2区医学

Seminars in Immunology Pub Date : 2025-09-01 Epub Date: 2025-08-28 DOI: 10.1016/j.smim.2025.101983

Camillo Bechi Genzano , Tyla Young , Rachel Bonami , Raniero Chimienti , Leonardo M.R. Ferreira , Emily K. Sims , Remi J. Creusot

{"title":"Autoimmune diabetes and targets for immunomodulation","authors":"Camillo Bechi Genzano , Tyla Young , Rachel Bonami , Raniero Chimienti , Leonardo M.R. Ferreira , Emily K. Sims , Remi J. Creusot","doi":"10.1016/j.smim.2025.101983","DOIUrl":"10.1016/j.smim.2025.101983","url":null,"abstract":"<div><div>In Type 1 diabetes (T1D), pancreatic β cells are progressively lost, resulting in insulin insufficiency. Although exogenous insulin is essential for disease management, it is not a cure, and inadequate glycemic control continues to result in long-term complications. Thus, there is a need for therapies that address the underlying autoimmune response, a key component of T1D pathogenesis. This review examines a wide range of actionable immunomodulatory targets at the tissue, cellular, and molecular levels that form the basis of current and emerging therapies for T1D. Particular emphasis is placed on T cell populations, which play a central role; with other immune cell types contributing to varying degrees also discussed. Immune-modifying therapies aim to prevent or reverse the pathogenic functions of these cells, including their interactions with β cells. Many of these approaches are directed at specific immune cell populations, but not only the pathogenic ones. Recent advances have enabled more precise targeting, based on tissue relevance or antigen specificity. The immune system may also be indirectly modulated by targeting the microbiome, offering potential new strategies for early prevention of T1D. Many of these targets were identified from animal models and remain to be validated in humans, leaving numerous therapeutic avenues open for exploration.</div></div>","PeriodicalId":49546,"journal":{"name":"Seminars in Immunology","volume":"79 ","pages":"Article 101983"},"PeriodicalIF":7.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144912206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Potential role of microbes in antigen-based food sensitivities. 微生物在抗原食物敏感性中的潜在作用。

IF 7.8 2区医学

Seminars in Immunology Pub Date : 2025-09-01 Epub Date: 2025-08-07 DOI: 10.1016/j.smim.2025.101982

Alberto Caminero, Elisa Sánchez-Martínez, Mark Wulczynski, Lucía Moreno-Serna, Elena F Verdu, Rodrigo Jiménez-Saiz

引用次数: 0

Oncolytic virus-mediated immunomodulation in glioblastoma: Insights from clinical trials and challenges 胶质母细胞瘤中溶瘤病毒介导的免疫调节：来自临床试验和挑战的见解

IF 7.4 2区医学

Seminars in Immunology Pub Date : 2025-09-01 Epub Date: 2025-06-23 DOI: 10.1016/j.smim.2025.101975

Raziye Piranlioglu , E. Antonio Chiocca

{"title":"Oncolytic virus-mediated immunomodulation in glioblastoma: Insights from clinical trials and challenges","authors":"Raziye Piranlioglu , E. Antonio Chiocca","doi":"10.1016/j.smim.2025.101975","DOIUrl":"10.1016/j.smim.2025.101975","url":null,"abstract":"<div><div>The pivotal involvement of the host immune system in cancer therapy has dramatically reshaped therapeutic paradigms, inaugurating the era of immunotherapy. Nonetheless, antigen-specific immunotherapies encounter substantial hurdles within the highly immunosuppressive microenvironment of glioblastoma (GBM), which thwarts antitumor T-cell immunity. Oncolytic viruses (OVs), a form of immunotherapy that inflames the GBM microenvironment, have been subject to clinical evaluation, yielding promising outcomes. Evidence increasingly indicates that OVs can modify the GBM microenvironment from an immunosuppressive to an immune active state, facilitating enhanced antitumor responses. Clinical trials demonstrate that oncolytic virotherapy is generally well-tolerated, generating data about its immune-activating effects. \"Window of opportunity\" trials provide insights into viral replication, pre-existing immunity, and delivery methods. However, constraints in post-treatment sampling may impede comprehensive analyses of the virotherapy-induced biological and immunological changes. This review discusses current advancements and persistent challenges in GBM trials involving OVs.</div></div>","PeriodicalId":49546,"journal":{"name":"Seminars in Immunology","volume":"79 ","pages":"Article 101975"},"PeriodicalIF":7.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144366301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diffuse neuropsychiatric lupus: Clinical evidence, immune-mediated mechanisms, and therapeutic insights 弥漫性神经精神性狼疮：临床证据、免疫介导机制和治疗见解

IF 7.8 2区医学

Seminars in Immunology Pub Date : 2025-09-01 Epub Date: 2025-08-15 DOI: 10.1016/j.smim.2025.101981

Rachel Weissman-Tsukamoto, Kaitlin R. Carroll, Betty Diamond

{"title":"Diffuse neuropsychiatric lupus: Clinical evidence, immune-mediated mechanisms, and therapeutic insights","authors":"Rachel Weissman-Tsukamoto, Kaitlin R. Carroll, Betty Diamond","doi":"10.1016/j.smim.2025.101981","DOIUrl":"10.1016/j.smim.2025.101981","url":null,"abstract":"<div><div>Neuropsychiatric manifestations of systemic lupus erythematosus (NPSLE) occur in more than half of patients with SLE, with symptoms including fatigue, anxiety, depression, pain, psychosis, and cognitive dysfunction. These symptoms are often present at the time of diagnosis of SLE and can be insidious. Patients consider these to be among their most debilitating symptoms which most diminish their quality of life, but recognition and attribution of these frequently non-acute symptoms can be difficult, resulting in underassessment, underdiagnosis, and poor understanding of the underlying pathogenic mechanisms and how to treat them. In this review, we highlight findings from neuroimaging studies which have been critical in proving the existence of structural and functional brain alterations that associate with symptomatology, and pathophysiological findings from animal models of diffuse NPSLE, focusing principally on blood brain barrier injury and brain-reactive autoantibodies. Most importantly, we demonstrate that mechanistic progress can be made with respect to these manifestations of NPSLE and that this progress leads to therapeutic strategies which can be tested in clinical trials.</div></div>","PeriodicalId":49546,"journal":{"name":"Seminars in Immunology","volume":"79 ","pages":"Article 101981"},"PeriodicalIF":7.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144841131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An evolutionary perspective of the roles of galectins in pathogen recognition and immunity 凝集素在病原体识别和免疫中的作用的进化观点

IF 7.4 2区医学

Seminars in Immunology Pub Date : 2025-09-01 Epub Date: 2025-06-16 DOI: 10.1016/j.smim.2025.101974

Gerardo R. Vasta , Gabriel A. Rabinovich

{"title":"An evolutionary perspective of the roles of galectins in pathogen recognition and immunity","authors":"Gerardo R. Vasta , Gabriel A. Rabinovich","doi":"10.1016/j.smim.2025.101974","DOIUrl":"10.1016/j.smim.2025.101974","url":null,"abstract":"<div><div>Protein-glycan interactions, mediated by lectins, are essential for diverse physiological processes, including glycoprotein processing, cell adhesion, communication, signaling, and immune recognition. Lectins, classified into families like C-type, I-type, F-type, and galectins, recognize specific glycans on macromolecules through their carbohydrate recognition domains (CRDs). Galectins, characterized by their β-galactoside binding and conserved CRD structure, exhibit remarkable functional diversification across evolution. Initially associated with developmental roles, they are now implicated in cancer, angiogenesis, and immune homeostasis. Furthermore, they interact with glycans on both beneficial and pathogenic microorganisms. While host galectins facilitate mutualistic interactions, pathogens can exploit this recognition for infection and manipulate host glycosylation to subvert galectin functions. The ability of galectins to recognize both self and non-self glycans, evident even in early metazoans, underscores their evolutionary versatility and raises questions about their primordial function and their evolutionary trajectory<strong>.</strong> This review explores the evolving roles of galectins, highlighting their adaptability and the complex interplay between host and pathogen interactions.</div></div>","PeriodicalId":49546,"journal":{"name":"Seminars in Immunology","volume":"79 ","pages":"Article 101974"},"PeriodicalIF":7.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144298566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Local and Cell-intrinsic complement: The new player in cancer progression 局部和细胞内在补体：癌症进展的新参与者

IF 7.4 2区医学

Seminars in Immunology Pub Date : 2025-09-01 Epub Date: 2025-06-24 DOI: 10.1016/j.smim.2025.101976

M. Revel , N.S. Merle

{"title":"Local and Cell-intrinsic complement: The new player in cancer progression","authors":"M. Revel , N.S. Merle","doi":"10.1016/j.smim.2025.101976","DOIUrl":"10.1016/j.smim.2025.101976","url":null,"abstract":"<div><div>The complement system, a key component of innate immunity, has a paradoxical role in cancer, acting both as a tumor suppressor and a promoter. While traditionally recognized for its extracellular immune functions, recent discoveries highlight non-canonical, intracellular roles in tumor progression. These findings challenge the conventional view that complement activity is confined to the extracellular space and reveal its unexpected influence on tumor proliferation, immune evasion, and metastasis. Tumors exploit local complement activation to create an immunosuppressive microenvironment, often upregulating regulatory proteins to evade complement-mediated cytotoxicity. Complement proteins can also promote tumor growth and therapy resistance through extracellular signaling and intracellular interactions with oncogenic pathways. The emerging concept of an intracellular complement system, or \"complosome,\" further suggests roles in cell metabolism, immune modulation, and stress responses. Despite these insights, key challenges remain in defining cell-specific complement functions and distinguishing autocrine, paracrine, and intracellular signaling. Current studies rely heavily on gene expression data, which do not fully reflect protein activity. Advances in gene editing, single-cell technologies, and intracellular complement inhibitors will be critical for clarifying the complex roles of complement in cancer and identifying new therapeutic strategies.</div></div>","PeriodicalId":49546,"journal":{"name":"Seminars in Immunology","volume":"79 ","pages":"Article 101976"},"PeriodicalIF":7.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144366300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epigenetic mechanisms in HCC immune landscape: Therapeutic implications 肝癌免疫景观的表观遗传机制：治疗意义

IF 7.8 2区医学

Seminars in Immunology Pub Date : 2025-09-01 Epub Date: 2025-07-29 DOI: 10.1016/j.smim.2025.101980

Maite G. Fernandez-Barrena , Iker Uriarte , Pablo Sarobe , Matias A. Avila

{"title":"Epigenetic mechanisms in HCC immune landscape: Therapeutic implications","authors":"Maite G. Fernandez-Barrena , Iker Uriarte , Pablo Sarobe , Matias A. Avila","doi":"10.1016/j.smim.2025.101980","DOIUrl":"10.1016/j.smim.2025.101980","url":null,"abstract":"<div><div>Hepatocellular carcinoma (HCC) is the most frequent primary liver tumor and is currently a major cause of cancer-related mortality worldwide. The arrival of immune checkpoint inhibitors (ICI), and their combination with anti-VEGF/VEGFR antibodies, has transformed the treatment of patients with advanced HCC. Still, only about 30 % of patients respond to therapy, and these cases are among those displaying an immune-enriched (“immune-hot”) tumor microenvironment (TME). Therefore, the identification of combination strategies that can overcome ICI resistance is of high relevance. Epigenetic alterations are increasingly recognized to impact on tumor development, contributing to practically all the hallmarks of cancer. These mechanisms not only promote the growth and survival of cancer cells, also determine the phenotype of immune cells and other components of the TME, driving tumor progression and resistance to therapies. Emerging preclinical evidence in different tumor types indicates that the combination with the so-called epi-drugs can increase the efficacy and overcome resistance to ICI. Here, we provide an overview of the epigenetic rewiring occurring in cancer and immune cells that can hinder antitumor immunity and ICI’s efficacy in HCC. We also discuss how epigenetically targeted therapies may be leveraged to synergize with ICI and potentially treat immune-cold HCCs.</div></div>","PeriodicalId":49546,"journal":{"name":"Seminars in Immunology","volume":"79 ","pages":"Article 101980"},"PeriodicalIF":7.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144721514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0